Resumen
A type 2 diabetes model, consisting in the sequential administration of nicotinamide-streptozotocin (225 y 65 mg/kg respectively) to male Wistar rats, was evaluated and subsequently treated with glibenclamide, by acute and subacute tests. Parallel designs were used; the first one to establish the nicotinamide dose which protects against the total destruction of β cells, produced by the streptozotocin and the second one to determine the glibenclamide dose that produces the hypoglycemic effect in the model. The evaluation was done by blood glucose measures and pancreas histological studies. The results showed that this model is adequate for the acute study, but it is necessary to test other nicotinamide doses which may efficiently protect pancreatic β cells from the total destruction produced by the streptozotocin, and that may be useful for subacute or chronic studies, in order to employ it for the efficiency evaluation of other hypoglycemiant drugs.
Título traducido de la contribución | Assessment of diabetes type 2 model to study the hypoglycemic activity of glibenclamide |
---|---|
Idioma original | Español |
Páginas (desde-hasta) | 5-11 |
Número de páginas | 7 |
Publicación | Revista Mexicana de Ciencias Farmaceuticas |
Volumen | 38 |
N.º | 3 |
Estado | Publicada - jul. 2007 |
Palabras clave
- Glibenclamide
- Histopathology
- Nicotinamide
- Streptozotocin
- Subacute administration
- Type 2 diabetes model